From: Circadian pathway genetic variation and cancer risk: evidence from genome-wide association studies
Gene | Chr | No. SNPs | P value | Cancer |
---|---|---|---|---|
RORA | 15 | 7 | 2.11E-04 | Breast_ER negative |
PER3 | 1 | 1 | 3.14E-04 | |
PER2 | 2 | 3 | 0.001 | |
CSNK1E | 22 | 1 | 0.002 | |
ARNTL2 | 12 | 1 | 0.004 | |
NPAS2 | 2 | 1 | 0.005 | |
PER1 | 17 | 1 | 0.009 | |
RORA | 15 | 12 | 4.50E-06 | Prostate_aggressive |
NPAS2 | 2 | 5 | 9.75E-05 | |
ARNTL | 11 | 2 | 1.90E-04 | |
RORB | 9 | 3 | 9.25E-04 | |
PER1 | 17 | 1 | 0.002 | |
PER3 | 1 | 4 | 0.004 | |
TIMELESS | 12 | 1 | 0.007 | |
RORA | 15 | 55 | 1.50E-06 | Lung_squamous |
RORB | 9 | 20 | 2.55E-05 | |
NPAS2 | 2 | 10 | 4.45E-05 | |
ARNTL | 11 | 17 | 0.001 | |
ARNTL2 | 12 | 5 | 0.001 | |
PER2 | 2 | 3 | 0.003 | |
NR1D2 | 3 | 3 | 0.010 | |
CLOCK | 4 | 2 | 0.012 | |
CRY1 | 12 | 1 | 0.023 | |
TIMELESS | 12 | 3 | 0.033 | |
RORC | 1 | 1 | 0.041 | |
CSNK1E | 22 | 1 | 0.044 | |
RORA | 15 | 45 | 2.00E-06 | Lung_adenocarcinoma |
RORB | 9 | 17 | 8.50E-06 | |
PER3 | 1 | 4 | 5.03E-04 | |
CLOCK | 4 | 2 | 0.001 | |
ARNTL2 | 12 | 3 | 0.001 | |
ARNTL | 11 | 8 | 0.003 | |
NR1D1 | 17 | 4 | 0.005 | |
NR1D2 | 3 | 3 | 0.008 | |
CSNK1E | 22 | 4 | 0.017 | |
NPAS2 | 2 | 2 | 0.021 | |
PER1 | 17 | 1 | 0.027 | |
RORC | 1 | 3 | 0.029 | |
CRY1 | 12 | 1 | 0.037 |